Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verastem (VSTM) Payables: 2018-2025

Historic Payables for Verastem (VSTM) over the last 8 years, with Sep 2025 value amounting to $10.1 million.

  • Verastem's Payables rose 120.43% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.6 million, marking a year-over-year increase of 20.30%. This contributed to the annual value of $4.0 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Verastem's Payables is $10.1 million, which was up 18.35% from $8.5 million recorded in Q2 2025.
  • In the past 5 years, Verastem's Payables registered a high of $10.1 million during Q3 2025, and its lowest value of $641,000 during Q3 2021.
  • Its 3-year average for Payables is $6.7 million, with a median of $6.6 million in 2023.
  • Per our database at Business Quant, Verastem's Payables crashed by 86.31% in 2021 and then surged by 736.04% in 2022.
  • Over the past 5 years, Verastem's Payables (Quarterly) stood at $2.3 million in 2021, then soared by 124.85% to $5.2 million in 2022, then declined by 1.77% to $5.3 million in 2023, then declined by 13.16% to $4.0 million in 2024, then surged by 120.43% to $10.1 million in 2025.
  • Its Payables was $10.1 million in Q3 2025, compared to $8.5 million in Q2 2025 and $7.9 million in Q1 2025.